The stock of TrovaGene Inc (NASDAQ:TROV) is a huge mover today! About 139,667 shares traded hands. TrovaGene Inc (NASDAQ:TROV) has declined 33.73% since March 9, 2016 and is downtrending. It has underperformed by 41.15% the S&P500.
The move comes after 6 months negative chart setup for the $119.53 million company. It was reported on Oct, 12 by Barchart.com. We have $3.53 PT which if reached, will make NASDAQ:TROV worth $16.73 million less.
Analysts await TrovaGene Inc (NASDAQ:TROV) to report earnings on November, 14. They expect $-0.32 earnings per share, up 13.51% or $0.05 from last year’s $-0.37 per share. After $-0.34 actual earnings per share reported by TrovaGene Inc for the previous quarter, Wall Street now forecasts -5.88% EPS growth.
TrovaGene Inc (NASDAQ:TROV) Ratings Coverage
Out of 5 analysts covering TrovaGene (NASDAQ:TROV), 0 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. TrovaGene has been the topic of 8 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The stock of TrovaGene Inc (NASDAQ:TROV) has “Outperform” rating given on Friday, August 14 by Leerink Swann. The stock of TrovaGene Inc (NASDAQ:TROV) has “Sector Perform” rating given on Tuesday, April 26 by Leerink Swann. The company was maintained on Tuesday, March 29 by Avondale. The rating was downgraded by Janney Capital to “Neutral” on Friday, March 11. Cantor Fitzgerald initiated TrovaGene Inc (NASDAQ:TROV) rating on Tuesday, September 15. Cantor Fitzgerald has “Buy” rating and $10 price target. As per Monday, April 25, the company rating was downgraded by Cantor Fitzgerald. The firm has “Neutral” rating given on Monday, April 25 by Piper Jaffray.
According to Zacks Investment Research, “Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism.”
Insitutional Activity: The institutional sentiment decreased to 0.81 in Q2 2016. Its down 0.84, from 1.65 in 2016Q1. The ratio worsened, as 8 funds sold all TrovaGene Inc shares owned while 23 reduced positions. 14 funds bought stakes while 11 increased positions. They now own 9.19 million shares or 9.18% less from 10.12 million shares in 2016Q1.
Blackrock Institutional Tru Na last reported 0% of its portfolio in the stock. Blackrock Inv Mngmt Ltd, a New Jersey-based fund reported 113,232 shares. Elkhorn Prtnrs L P, a Nebraska-based fund reported 55,913 shares. Da Davidson, a Montana-based fund reported 207,373 shares. Blackrock Fund holds 742,523 shares or 0% of its portfolio. Blackrock has 0% invested in the company for 2,200 shares. First Heartland Consultants holds 0.01% or 22,800 shares in its portfolio. Goldman Sachs Grp has invested 0% of its portfolio in TrovaGene Inc (NASDAQ:TROV). California State Teachers Retirement accumulated 0% or 59,077 shares. Bluestein R H owns 20,000 shares or 0.01% of their US portfolio. Moreover, Teachers Advsr Inc has 0% invested in TrovaGene Inc (NASDAQ:TROV) for 48,120 shares. D E Shaw Inc holds 15,104 shares or 0% of its portfolio. Windsor Grp Ltd Liability reported 62,500 shares or 0.13% of all its holdings. Bnp Paribas Arbitrage holds 0% or 1,478 shares in its portfolio. Creative Planning last reported 0% of its portfolio in the stock.
More notable recent TrovaGene Inc (NASDAQ:TROV) news were published by: Prnewswire.com which released: “Trovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference” on July 05, 2016, also Prnewswire.com with their article: “Trovagene to Present at the 3rd Annual Precision Medicine Congress” published on September 09, 2016, Prnewswire.com published: “Trovagene Schedules Release of Second Quarter 2016 Financial Results and …” on July 26, 2016. More interesting news about TrovaGene Inc (NASDAQ:TROV) were released by: Prnewswire.com and their article: “Trovagene and University of Michigan Enter into Collaboration for Monitoring …” published on July 06, 2016 as well as Zacks.com‘s news article titled: “Why Is Trovagene Inc. (TROV) Stock Soaring Today?” with publication date: January 21, 2016.
TROV Company Profile
Trovagene, Inc. (TrovaGene), incorporated on September 21, 2009, is a molecular diagnostic company. The Firm focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. The Company’s primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. The Firm has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.